by Guest Contributer | Mar 27, 2025 | DOT, Drug & Alcohol Testing, Feature, Marijuana & CBD
By Jonathan Baktari, MD, US Drug Test Centers With evolving legislation, the legalization of certain drugs continues to change. There have been a lot of question marks around THC, the psychoactive substance in marijuana. Over the years, we’ve watched as the...
by NDASA | Aug 28, 2024 | Advocacy, Feature, Marijuana & CBD
This week, the Drug Enforcement Administration (DEA) administrator issued a Notice of Hearing that is expected to publish in the Federal Register on Thursday, August 29. (Click here to review the Notice of Hearing) In the document, the DEA announced that a hearing on...
by Guest Contributer | Jul 18, 2024 | Advocacy, Drug Legislation, Marijuana & CBD, Workplace Safety
By Bill Current, Founder of the Current Consulting Group Did you know the Drug Enforcement Administration’s (DEA) mission is to “enforce the controlled substances laws and regulations of the United States… and support non-enforcement programs aimed at reducing the...
by NDASA | Jun 14, 2024 | Advocacy, Drug & Alcohol Testing, Drug Legislation, Feature, Resources
Make your voice heard! You can have an impact on the U.S. Drug Enforcement Administration’s proposal to reschedule marijuana from a Schedule I drug to a Schedule III drug under the Controlled Substances Act by providing comment to the NPRM. The deadline for submitting...
by Guest Contributer | May 3, 2024 | Drug Legislation, Feature, Industry News, Uncategorized
Courtesy of American Substance Abuse Professionals AP News reports that the US Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug. Reclassifying marijuana as a less dangerous drug creates medical and...
